With Bydureon’s U.S. Approval, Amylin Extends Exenatide Franchise
This article was originally published in The Pink Sheet Daily
Executive Summary
Twice delayed by “complete response” letters, the drug’s approval gives Amylin a once-weekly GLP-1 analog, the longest-acting drug in its class.
You may also be interested in...
On The Wings Of Lantus: Sanofi Sees Clearer Skies Ahead In Diabetes
With the removal of a near-term competitive threat to Sanofi’s hallmark insulin franchise, 2013 is poised to be a momentum-building year for the big pharma, and more specifically, its diabetes business. The opportunity can’t come too soon, as the company launches the GLP-1 agonist Lyxumia into a crowded and fiercely competitive field.
Bristol And AstraZeneca Make A Splash In Diabetes With Joint Purchase Of Amylin
Bristol-Myers’ and AstraZeneca’s deal to acquire Amylin Pharmaceuticals for $7 billion, announced June 29, reaffirms the partners’ commitment to the vast and growing type 2 diabetes market, even if the competition is intense and the companies’ five-year-old alliance got off to a rocky start.
PhaseBio Diabetes Program Reaches Inflection Point With Series B Add-On
Privately held biotech announces an additional $23 million raise from existing investors to finance a head-to-head Phase IIb trial for its GLP-1 analogue against Victoza.